Search

Your search keyword '"Katz, L. Jay"' showing total 739 results
Start Over Author "Katz, L. Jay"
739 results on '"Katz, L. Jay"'

7. Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension

Author

Ang, Robert E., Heersink, Sebastian B., Vold, Steven, Atodaria, Neil, Brubaker, Jacob, Goldberg, Damien, Lin, Christopher, Nguyen, Betsy, Schultz, Mitchell, Silverstein, Bruce, Sorenson, Robert, Bashford, Kent, Burden, James H., ElMallah, Mohammed, Kim, Joshua, Lambright, Benjamin, McCabe, Cathleen, Shetty, Rajesh, Smith, Steven, Tyson, Farrell, Jones, Jason, D’Ambrosio, Francis, Wu, Bin, Basha, Mahdi, Chu, Ralph, Gira, Joseph, Swan, Russell, Baartman, Brandon, Wellish, Kent, Sarkisian, Steven R., Jr., Lee, Andy M., Berdahl, John P., Doan, Long V., Stephens, Kerry G., Kothe, Angela C., Usner, Dale W., Katz, L. Jay, and Navratil, Tomas

Published
2024
Full Text
View/download PDF

8. List of contributors

Author

Ahmad, Hanif, primary, Alany, Raid G., additional, Alió, Jorge L., additional, Anderson, Andrew J., additional, Arora, Anmol, additional, Azuara-Blanco, Augusto, additional, Barrio, Jorge Alio del, additional, Baudouin, Christophe, additional, Bou Said, Reeda, additional, Bourne, Rupert R.A., additional, Butt, Fatima, additional, Calkins, David J., additional, Chan, Geoffrey Z.P., additional, Cheng, Ching-Yu, additional, Chong, Rachel S., additional, Cordeiro, Maria Francesca, additional, Crowston, Jonathan G., additional, Daka, Qëndresë, additional, Daneshvar, Ramin, additional, Denniss, Jonathan, additional, Deol, Sundeep Singh, additional, Epstein, Rebecca, additional, Ertel, Monica, additional, Fam, Jonathan M., additional, Fellman, Ronald L., additional, Garway-Heath, Ted, additional, Gazzard, Gus, additional, Gilbert, Clare, additional, Gillmann, Kevin, additional, Goldberg, Ivan, additional, Goldberg, Jeffrey L., additional, Grover, Sumit, additional, Heatley, Gregg A., additional, Hoffmann M., Esther, additional, Huang, Alex S., additional, Jin, Zi-Bing, additional, Johnstone, Murray, additional, Kahook, Malik, additional, Katz, L. Jay, additional, Kaufman, Paul L., additional, Keane, Pearse A., additional, Khawaja, Anthony P., additional, Khoueir, Ziad, additional, Lawlor, Mitchell, additional, Leung, Christopher, additional, Malyugin, Boris, additional, Mansberger, Steven L., additional, Mansouri, Kaweh, additional, Martin, Keith R., additional, Martinez, Christine E., additional, McKendrick, Allison M., additional, Mermoud, André, additional, Nickells, Robert W., additional, Nouri-Mahdavi, Kouros, additional, Oostra, Tyler D., additional, Palko, Joel, additional, Patel, Radhika Pooja, additional, Pradhan, Zia S., additional, Priyanka, Ramesh, additional, Rao, Harsha L., additional, Razeghinejad, Reza, additional, Realini, Tony, additional, Ritch, Robert, additional, Roy, Sylvain, additional, Sailer, Kerstin, additional, Sanchez, Facundo G., additional, Schlötzer-Schrehardt, Ursula, additional, Schuman, Joel S., additional, Scott, Andrew, additional, Seibold, Leonard, additional, Sharma, Anant, additional, Spaeth, George, additional, Strohmaier, Clemens A., additional, Szymanska, Maja, additional, Tanna, Angelo P., additional, Tanuj, Dada, additional, Tapply, Ian H., additional, Tatham, Andrew J., additional, Toris, Carol B., additional, Tsasousis, Konstantinos T., additional, Wang, Ningli, additional, Weinreb, Robert N., additional, Wiggs, Janey L., additional, Wo, Yu Jun, additional, Wollstein, Gadi, additional, Wu, Shen, additional, Wu, Zhichao, additional, Xin, Chen, additional, Yoo, Chungkwon, additional, Young, Cara Capitena, additional, and Zhang, Jingxue, additional

Published
2023
Full Text
View/download PDF

12. Glaucoma

Author

Sinha, Sapna, primary, Shalaby, Wesam Shamseldin, additional, Liu, Wendy W., additional, Razeghinejad, Reza, additional, and Katz, L. Jay, additional

Published
2022
Full Text
View/download PDF

13. Mutations of conserved non-coding elements of PITX2 in patients with ocular dysgenesis and developmental glaucoma

Author

Protas, Meredith E, Weh, Eric, Footz, Tim, Kasberger, Jay, Baraban, Scott C, Levin, Alex V, Katz, L Jay, Ritch, Robert, Walter, Michael A, Semina, Elena V, and Gould, Douglas B

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Genetics, Congenital Structural Anomalies, Pediatric, Human Genome, Eye Disease and Disorders of Vision, Mental Health, Neurodegenerative, Aetiology, 2.1 Biological and endogenous factors, Animals, Anterior Eye Segment, Conserved Sequence, DNA Copy Number Variations, Disease Models, Animal, Eye Abnormalities, Gene Deletion, Glaucoma, Homeodomain Proteins, Humans, Introns, Muscles, Mutation, Pedigree, Sequence Deletion, Transcription Factors, Zebrafish, Homeobox Protein PITX2, Medical and Health Sciences, Genetics & Heredity
Abstract

Mutations in FOXC1 and PITX2 constitute the most common causes of ocular anterior segment dysgenesis (ASD), and confer a high risk for secondary glaucoma. The genetic causes underlying ASD in approximately half of patients remain unknown, despite many of them being screened by whole exome sequencing. Here, we performed whole genome sequencing on DNA from two affected individuals from a family with dominantly inherited ASD and glaucoma to identify a 748-kb deletion in a gene desert that contains conserved putative PITX2 regulatory elements. We used CRISPR/Cas9 to delete the orthologous region in zebrafish in order to test the pathogenicity of this structural variant. Deletion in zebrafish reduced pitx2 expression during development and resulted in shallow anterior chambers. We screened additional patients for copy number variation of the putative regulatory elements and found an overlapping deletion in a second family and in a potentially-ancestrally-related index patient with ASD and glaucoma. These data suggest that mutations affecting conserved non-coding elements of PITX2 may constitute an important class of mutations in patients with ASD for whom the molecular cause of their disease have not yet been identified. Improved functional annotation of the human genome and transition to sequencing of patient genomes instead of exomes will be required before the magnitude of this class of mutations is fully understood.

Published
2017

15. A Proposal for the Use of a Fixed Low-Energy Selective Laser Trabeculoplasty for Open Angle Glaucoma

Author

Sacks, Zachary, Katz, L. Jay, Gazzard, Gus, Van Tassel, Sarah H., Blumenthal, Eytan Z., Lerner, Fabian S., Azuara-Blanco, Augusto, Spooner, Gregory John Roy, Solberg, Yoram, Samuelson, Thomas, Belkin, Michael, Sacks, Zachary, Katz, L. Jay, Gazzard, Gus, Van Tassel, Sarah H., Blumenthal, Eytan Z., Lerner, Fabian S., Azuara-Blanco, Augusto, Spooner, Gregory John Roy, Solberg, Yoram, Samuelson, Thomas, and Belkin, Michael

Abstract

Selective laser trabeculoplasty (SLT) has been in routine clinical use for over 20 years with millions of patients successfully treated and a low rate of clinically significant complications. The procedure requires the clinician to manually position the laser beam on the trabecular meshwork using a gonioscopy lens and to titrate the SLT laser energy based on the amount of pigmentation in the angle, as well as the observation of small bubbles produced by the laser effect. We propose that SLT energy titration is unnecessary either to achieve intraocular pressure (IOP) reduction or to minimize potential side effects. Ample evidence to support our proposal includes multiple clinical reports demonstrating comparable levels of IOP reduction resulting from different laser energies, a large variety of energy and other laser parameters used in commercially available SLT lasers, and the nature of the laser-induced changes in the trabecular meshwork tissue with respect to energy. Despite these variations in laser parameters, SLT consistently reduces IOP with a low complication rate. We propose that using low fixed energy for all patients will effectively and safely lower patients' IOP while reducing the complexity of the SLT procedure, potentially making SLT accessible to more patients.

Published
2024

16. Contemporary Approach to Narrow Angles

Author

Shalaby, Wesam Shamseldin, Reddy, Rohit, Razeghinejad, Reza, Katz, L. Jay, Shalaby, Wesam Shamseldin, Reddy, Rohit, Razeghinejad, Reza, and Katz, L. Jay

Abstract

Glaucoma is the leading cause of irreversible blindness worldwide. Among all glaucoma types, primary angle closure glaucoma (PACG) affects approximately 23 million people worldwide, and is responsible for 50% of glaucoma-related blindness, highlighting the devastating consequences of this disease. The main mechanism of PACG is relative pupillary block. High-risk populations are female gender, Asian ethnicity, high hyperopia, short axial length, and a thick/anteriorly positioned lens. This review discusses the clinical diagnosis, classification, and management of patients with a narrow angle with and without intraocular pressure (IOP) elevation and glaucomatous optic nerve damage, including laser peripheral iridotomy (LPI), endocycloplasty (ECPL), lens extraction, and goniosynechialysis.

Published
2024

19. Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension

Author

Sarkisian, Steven R., primary, Ang, Robert E., additional, Lee, Andy M., additional, Berdahl, John P., additional, Heersink, Sebastian B., additional, Burden, James H., additional, Doan, Long V., additional, Stephens, Kerry G., additional, Kothe, Angela C., additional, Usner, Dale W., additional, Katz, L. Jay, additional, and Navratil, Tomas, additional

Published
2024
Full Text
View/download PDF

28. Is Glaucoma a Reversible Disease?

Author

Katz, L. Jay

Subjects
Glaucoma -- Care and treatment, Intraocular pressure -- Health aspects -- Control, Stem cell research, Bimatoprost, Health
Abstract

The field of glaucoma has made great strides in diagnosis, treatment and management, but in order to take the next quantum leap for our patients, we have to drop one [...]

Published
2019

31. Effect of Phacoemulsification on Intraocular Pressure in Eyes With Functioning Tube Shunts

Author

Shalaby, Wesam Shamseldin, Patel, Sonali, Lam, Sophia, Ganjei, Allen, Shukla, Aakriti Garg, Kolomeyer, Natasha, Lee, Daniel, Katz, L. Jay, Moster, Marlene, Myers, Jonathan, Razeghinejad, Reza, Shalaby, Wesam Shamseldin, Patel, Sonali, Lam, Sophia, Ganjei, Allen, Shukla, Aakriti Garg, Kolomeyer, Natasha, Lee, Daniel, Katz, L. Jay, Moster, Marlene, Myers, Jonathan, and Razeghinejad, Reza

Abstract

Purpose: To evaluate the effect of phacoemulsification on intraocular pressure (IOP) in eyes with functioning tube shunts. Methods: This was a retrospective chart review of primary open-angle glaucoma (POAG) patients with a functioning tube who underwent phacoemulsification and had ≥24 months of follow-up. The primary end point was defined as surgical failure (IOP > 21 mmHg) at month 24, progression to no light perception (NLP) vision, glaucoma reoperation, or implant removal. Surgical failure defined as IOP >18 and >15 mmHg, changes in visual acuity (VA), IOP, and number of medications were assessed. Results: Twenty-seven eyes of 27 patients with moderate or severe POAG were included. The mean age of the patients was 64.2 ± 10.8 years. The interval between the tube shunt and phacoemulsification was 28.8 ± 25.0 months. At the end of the study, four (14.8%) eyes met the failure criteria; the average time to failure was 9.3 ± 3.8 months. The causes of failure were high IOP in two (50.0%) and glaucoma reoperation in two (50.0%) eyes; however, no eyes progressed to NLP vision. Surgical failure defined as IOP >18 and >15 mmHg showed an increasing failure rate (18.5% and 48.5%, respectively). The mean IOP and medications number remained stable at month 24 compared to baseline (P = 0.131 and P = 0.302, respectively). Initially, VA showed improvement, with the greatest improvement at 6 months (P = 0.001), but at 24 months the improvement was no longer significant (P = 0.430). Conclusion: Phacoemulsification in patients with functioning tubes did not change the mean IOP in most of the patients (86.2%); the number of medications also did not increase.

Published
2023

35. The long-term clinical outcomes of latanoprostene bunod 0.024% in glaucoma treatment at a tertiary glaucoma center.

Author

Wong, Jae-Chiang, Neustein, Rebecca F., Ustaoglu, Melih, Shiuey, Eric, Mehran, Nikki, Moster, Marlene R., Razeghinejad, Reza, Katz, L. Jay, Myers, Jonathan, and Lee, Daniel

Subjects
GLAUCOMA surgery, DRUG efficacy, PROSTAGLANDINS, HOSPITALS, GLAUCOMA, INTRAOCULAR pressure, GENERIC drug substitution, OCULAR hypertension, TIME, RETROSPECTIVE studies, TERTIARY care, FISHER exact test, MANN Whitney U Test, OPHTHALMIC drugs, PRE-tests & post-tests, COMPARATIVE studies, CRONBACH'S alpha, TREATMENT failure, DESCRIPTIVE statistics, VISUAL acuity, KAPLAN-Meier estimator, RESEARCH funding, DATA analysis software, TERMINATION of treatment, LONGITUDINAL method, EVALUATION
Abstract

To evaluate the clinical outcomes of latanoprostene bunod 0.024% (LB) in intraocular pressure (IOP) control in patients with glaucoma. This retrospective cohort study analyzed eyes treated with LB between 01/2018 and 01/2020. Demographic and clinical data were collected at baseline and up to 24-months (mo). Primary outcomes were mean change in IOP (∆IOP) from baseline in eyes switched from a prostaglandin analogue (PGA) to LB (Group 1) vs. eyes in which LB was added as a first PGA to a glaucoma regimen (Group 2). 262 eyes of 162 patients were included. Overall, baseline IOP was 18.67 ± 5.65 mmHg. Group 1 (n = 168 [64%]) and Group 2 (n = 66 [25%]) each individually had significant ∆IOP at 1, 3, 6, 12, and 18 mo compared to baseline (p = 0.005). ∆IOP and duration of IOP control (9.5 ± 11.4 vs. 9.7 ± 9.9 months) on LB was similar between Group 1 and 2 at all time points. Additional pharmacologic or surgical intervention was required in 71 (27%) and 66 (25%) eyes, respectively, and LB was stopped in 24 (9.1%) eyes due to side effects. LB successfully reduced IOP and was well-tolerated in our cohort. PGA naivete does not seem to influence the LB efficacy or its duration of effect. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs

Author

Londin, Eric, Loher, Phillipe, Telonis, Aristeidis G., Quann, Kevin, Clark, Peter, Jing, Yi, Hatzimichael, Eleftheria, Kirino, Yohei, Honda, Shozo, Lally, Michelle, Ramratnam, Bharat, Comstock, Clay E. S., Knudsen, Karen E., Gomella, Leonard, Spaeth, George L., Hark, Lisa, Katz, L. Jay, Witkiewicz, Agnieszka, Rostami, Abdolmohamad, Jimenez, Sergio A., Hollingsworth, Michael A., Yeh, Jen Jen, Shaw, Chad A., McKenzie, Steven E., Bray, Paul, Nelson, Peter T., Zupo, Simona, Van Roosbroeck, Katrien, Keating, Michael J., Calin, George A., Yeo, Charles, Jimbo, Masaya, Cozzitorto, Joseph, Brody, Jonathan R., Delgrosso, Kathleen, Mattick, John S., Fortina, Paolo, and Rigoutsos, Isidore

Published
2015

49. Outcomes of Ahmed glaucoma valve and transscleral cyclophotocoagulation in neovascular glaucoma

Author

Shalaby, Wesam S, Ganjei, Allen Y, Wogu, Brian, Myers, Jonathan S, Moster, Marlene R, Razeghinejad, Reza, Lee, Daniel, Kolomeyer, Natasha N, Eid, Tarek E, Katz, L Jay, Shukla, Aakriti Garg, Shalaby, Wesam S, Ganjei, Allen Y, Wogu, Brian, Myers, Jonathan S, Moster, Marlene R, Razeghinejad, Reza, Lee, Daniel, Kolomeyer, Natasha N, Eid, Tarek E, Katz, L Jay, and Shukla, Aakriti Garg

Abstract

Purpose: To determine the outcomes of Ahmed glaucoma valve (AGV) and transscleral diode cyclophotocoagulation (CPC) in neovascular glaucoma (NVG). Methods: This was a single-center retrospective comparative case series involving chart review of consecutive patients who underwent AGV or CPC for treatment of NVG and had ≥6 months of follow-up. Surgical failure at 6 months, defined as an IOP of >21 or <6 mm Hg with hypotony maculopathy after 1 month, progression to no light perception (NLP) vision, glaucoma reoperation, or removal of AGV were the main outcome measures. Results: In total, 121 eyes of 121 patients were included (70 AGV and 51 CPC). Baseline demographics, visual acuity (VA), and intraocular pressure (IOP) were comparable between groups. At 6 months, failure was significantly higher in the CPC group than in the AGV group (43.1% vs. 17.1%, P = 0.020). Both groups had similar IOP and medication number at 6 months, but VA was significantly lower in the CPC group compared to the AGV group (2.4 ± 0.8 vs. 1.9 ± 1.0, P = 0.017). More CPC eyes required reoperation for glaucoma than AGV eyes (11.8% vs. 1.4%, P = 0.041). Multivariate regression analysis identified higher preoperative IOP (P = 0.001) and CPC surgery (P = 0.004) as independent predictors of surgical failure at 6 months. Age, sex, race, NVG etiology, bilaterality of the underlying retinal pathology, perioperative retina treatment, and prior or combined vitrectomy were not significant. Conclusion: AGV and CPC had comparable IOP and medication reduction in NVG eyes at 6 months. CPC was more frequently associated with failure, reoperation for glaucoma, and worse visual outcomes. High preoperative IOP and CPC surgery independently predicted surgical failure.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results